ProShare Advisors LLC Purchases 3,714 Shares of Hologic, Inc. (NASDAQ:HOLX)

ProShare Advisors LLC grew its position in Hologic, Inc. (NASDAQ:HOLX) by 9.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 42,164 shares of the medical equipment provider’s stock after buying an additional 3,714 shares during the period. ProShare Advisors LLC’s holdings in Hologic were worth $3,040,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of HOLX. Venturi Wealth Management LLC boosted its holdings in shares of Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after buying an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 260 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after buying an additional 159 shares in the last quarter. Smithfield Trust Co boosted its holdings in shares of Hologic by 160.0% in the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 400 shares in the last quarter. Finally, Sound Income Strategies LLC bought a new stake in shares of Hologic in the 4th quarter valued at about $60,000. 94.73% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

HOLX has been the subject of a number of recent analyst reports. Leerink Partnrs cut shares of Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. StockNews.com cut shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, May 5th. Stephens decreased their price objective on shares of Hologic from $77.00 to $70.00 and set an “overweight” rating for the company in a research note on Tuesday, May 13th. Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Finally, Citigroup dropped their price objective on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Twelve analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Hologic has an average rating of “Hold” and an average target price of $77.42.

Hologic Stock Performance

HOLX opened at $56.43 on Tuesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The firm has a fifty day moving average price of $58.67 and a 200 day moving average price of $67.14. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.67. The stock has a market cap of $12.58 billion, a P/E ratio of 17.80, a P/E/G ratio of 2.14 and a beta of 0.54.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. During the same period in the previous year, the business posted $1.03 EPS. The business’s revenue was down 1.2% compared to the same quarter last year. Equities research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Activity at Hologic

In related news, Director Martin D. Madaus purchased 5,445 shares of the business’s stock in a transaction that occurred on Wednesday, May 7th. The stock was bought at an average price of $55.24 per share, with a total value of $300,781.80. Following the acquisition, the director now owns 5,445 shares in the company, valued at $300,781.80. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.88% of the company’s stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.